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In Brief
Baeza-Raja et al. report that p75
neurotrophin receptor (p75NTR) promotes
obesity and the metabolic syndrome.
Loss of p75NTR increases cAMP/PKA
signaling in adipocytes, increases energy
expenditure, and protects from diet-
induced obesity. Manipulating non-CNS
functions of neurotrophin receptor
signaling could provide a therapeutic
approach for obesity and the metabolic
syndrome.
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Obesity and metabolic syndrome reflect the dysre-
gulation of molecular pathways that control energy
homeostasis. Here, we show that the p75 neurotro-
phin receptor (p75NTR) controls energy expenditure
in obese mice on a high-fat diet (HFD). Despite no
changes in food intake, p75NTR-null mice were pro-
tected from HFD-induced obesity and remained
lean as a result of increased energy expenditure
without developing insulin resistance or liver steato-
sis. p75NTR directly interacts with the catalytic sub-
unit of protein kinase A (PKA) and regulates cAMP
signaling in adipocytes, leading to decreased lipol-
ysis and thermogenesis. Adipocyte-specific deple-
tion of p75NTR or transplantation of p75NTR-null white
adipose tissue (WAT) into wild-type mice fed a HFD
protected against weight gain and insulin resistance.
Our results reveal that signaling from p75NTR to
cAMP/PKA regulates energy balance and suggest
that non-CNS neurotrophin receptor signaling could
be a target for treating obesity and the metabolic
syndrome.INTRODUCTION
Obesity, and the ensuing metabolic syndrome characterized by
type 2 diabetes, hepatic steatosis, and atherosclerosis, is a
worldwide epidemic that increases morbidity and mortality.
Obesity develops when energy intake chronically exceeds en-
ergy expenditure (Spiegelman and Flier, 2001). While many fac-
tors control weight gain, glucose, and lipidmetabolism (O’Rahilly
and Farooqi, 2006), the molecular mechanisms that dysregulate
energy balance remain poorly understood. By understanding
these mechanisms, we can develop treatments for obesity and
its comorbidities.CStudies on energy intake have identified several pathways that
control appetite and hypothalamic functions, including leptin,
neuropeptide Y, and melanocortin receptors (Spiegelman and
Flier, 2001). Intriguingly, neurotrophin activation of cognate tyro-
sine kinase (Trk) receptors correlates with hypothalamic sup-
pression of appetite control. Indeed, brain-derived neurotrophic
factor (BDNF) signals through TrkB in the hypothalamus to sup-
press appetite and reduce body weight (Lyons et al., 1999; Xu
et al., 2003b). On a normal diet, BDNF+/ mice (Lyons et al.,
1999) or mice conditionally depleted of BDNF in neurons (Xu
et al., 2003b) overeat and become obese. These results suggest
that neurotrophin receptor signaling affects how the CNS con-
trols energy intake and body weight.
Neurotrophins and their receptors are also expressed in
several peripheral metabolic tissues, suggesting that non-CNS
molecular networks might regulate energy expenditure. Here,
we report that loss of p75 neurotrophin receptor (p75NTR) pro-
tects mice from obesity and the metabolic syndrome. p75NTR
regulates energy expenditure and thermogenesis, and its adipo-
cyte-specific depletion reduces obesity. These findings suggest
that manipulating non-CNS functions of p75NTR signaling could
provide a new therapeutic approach for obesity and the meta-
bolic syndrome.
RESULTS
p75NTR Knockout Mice Are Resistant to HFD-Induced
Obesity, Insulin Resistance, and Hepatic Steatosis
p75NTR is widely expressed in metabolic tissues, including liver
(Cassiman et al., 2001; Passino et al., 2007), white adipose tissue
(WAT) (Baeza-Raja et al., 2012; Peeraully et al., 2004), and skel-
etal muscle (Deponti et al., 2009), but we do not know whether it
affects obesity. p75NTR expression increased in WAT after
3 weeks of a high-fat diet (HFD), but not in skeletal muscle or liver
(Figure 1A). p75NTR was also highly expressed in differentiated
3T3L1 adipocytes and mouse embryonic fibroblast (MEF)-
derived adipocytes (Figure S1A). To evaluate whether p75NTR af-
fects obesity, p75NTR/ mice were placed on a HFD andell Reports 14, 255–268, January 12, 2016 ª2016 The Authors 255
Figure 1. p75NTR Deficiency Protects Mice from HFD-Induced Obesity and Metabolic Syndrome
(A) p75NTR protein (left) and RNA (right) expression in WAT, skeletal muscle (SKM), and liver fromWT and p75NTR/mice on normal diet (ND) and 3 and 8 weeks
(w) on a HFD. Representative immunoblot is shown from three independent experiments.
(B) Body weight of WT and p75NTR/ mice on a HFD. *p < 0.01; **p < 0.001, two-way ANOVA. n = 7 mice per group.
(C) Representative MRI images of WT and p75NTR/ mice on a HFD (left) and tissue volumes of WT and p75NTR/ mice on a HFD (right). **p < 0.01; ns, not
significant, unpaired Student’s t test. n = 7 mice per group.
(D) Weights of WT and p75NTR/ inguinal and intraperitoneal (IP) fat on a HFD. *p < 0.05, ***p < 0.001, unpaired Student’s t test. n = 7 mice per group.
(E) Basal insulin levels from WT and p75NTR/ mice. **p < 0.01; ns, unpaired Student’s t test. n = 4 mice per group.
(F and G) Glucose tolerance (F) and insulin tolerance (G) tests in WT (n = 13) and p75NTR/ (n = 8) mice after 20 weeks on HFD. *p < 0.05; **p < 0.01; ***p < 0.001,
two-way ANOVA.
(H) Glucose infusion rates from WT (n = 5) and p75NTR/ (n = 7) mice on an HFD. *p < 0.05, unpaired Student’s t test.
(I) Total and insulin-stimulated GDRs of WT (n = 5) and p75NTR/ (n = 7) mice on an HFD. *p < 0.05, unpaired Student’s t test.
(J) Representatives photographs (top) and histological images (bottom) of livers from WT and p75NTR/ mice on an HFD (n = 3 mice per group).
Data are shown as means ± SEM.
See also Figures S1 and S2.compared to their wild-type (WT) littermates. Interestingly,
p75NTR/ mice were resistant to weight gain and remained
lean after several weeks on a HFD compared to controls (Figures
1B and S1B). p75NTR/ mice also showed reduced adiposity,
fat volume, and total weight of inguinal and intraperitoneal fat
pads (Figures 1C and 1D). Weight did not differ between
p75NTR+/ and WT mice on a HFD (Figure S1C). Adipocytes
were 4-fold larger in control than in p75NTR/ fat pads from
mice on a HFD (Figure S1D). After just 3 weeks on a HFD, adipo-
cytes in WT mice were enlarged, while epididymal fat from
p75NTR/ mice contained smaller adipocytes (Figure S1E).
Obesity is a key trigger for type 2 diabetes, so we explored
whether p75NTR/ mice are protected from insulin resistance.
Basal insulin levels were 3-fold higher in WT than in p75NTR/256 Cell Reports 14, 255–268, January 12, 2016 ª2016 The Authorsmice on a HFD (Figure 1E). p75NTR/ mice also displayed
increased insulin sensitivity, markedly improved glucose toler-
ance, and enhanced glucose lowering effects of insulin (Figures
1F, 1G, and S1F). With the hyperinsulinemic-euglycemic clamp
technique, we found that glucose infusion rates were higher in
p75NTR/ mice than in WT mice on a HFD (Figure 1H), demon-
strating improved systemic insulin sensitivity. Furthermore,
tracer-derived Rd or glucose disposal rate (GDR) and insulin-
stimulated GDR were higher in p75NTR/ mice (Figure 1I), indi-
cating increased muscle insulin sensitivity. Basal hepatic
glucose production (HGP) did not change in p75NTR/ mice,
but insulin-induced suppression of HGP increased from 40%
to 64% (Figures S1G and S1H), showing decreased hepatic in-
sulin resistance induced by a HFD.
Figure 2. p75NTR Deficiency Increases
Energy Expenditure, Fat Oxidation, and
Lipolysis
(A) Food consumption (left) and energy intake
(right) of WT (n = 7) and p75NTR/ (n = 8) mice
on a HFD. ns, not significant, unpaired Student’s
t test.
(B) Oxygen consumption (left) and energy expen-
diture (right) normalized to lean body mass in WT
(n = 7) and p75NTR/ (n = 8) mice on a HFD. **p <
0.01; ***p < 0.001, Student’s t test.
(C) Fat oxidation normalized to lean body mass in
WT and p75NTR–/– mice on a HFD. ***p < 0.001,
unpaired Student’s t test. n = 6 mice per group.
(D) Oxidation of [1-14C]-palmitate to 14CO2 by ad-
ipocytes isolated from WT and p75NTR/ mice.
**p < 0.01, unpaired Student’s t test. Results are
from three independent experiments.
(E) Ucp1 and Dio2 RNA expression in primary ad-
ipocytes from WT and p75NTR/mice. **p < 0.01,
unpaired Student’s t test. n = 6 mice per group.
(F) Serum levels of adiponectin in WT and
p75NTR/ mice on a HFD. *p < 0.05, unpaired
Student’s t test. n = 3 mice per group.
Data are shown as means ± SEM.
See also Figures S3 and S4.HFD triggers non-alcoholic fatty liver disease, which can cause
liver steatosis, cirrhosis, and hepatocellular cancer (Osterreicher
andBrenner, 2007). After 16weeks on aHFD, controlmice devel-
oped and massively accumulated hepatic lipids and had
increased liver weight, as expected, while p75NTR/ mice were
protected (Figures 1J and S2A). Livers from p75NTR/ mice on
a HFD did not have higher levels of Sterol Regulatory Element-
Binding Protein 1 (SREBP-1) (Figure S2B), a transcription factor
that drives lipogenesis andmolecularlymarks liver steatosis (Shi-
momura et al., 1999). Liver triglycerides, SREBP-1 target genes,
fatty-acid-uptake genes, and fatty-acid-oxidation genes were
reduced in p75NTR/mice compared toWTmice on a HFD (Fig-
ures S2C and S2D). Moreover, p75NTR/ mice were protected
from increased cholesterol and HFD-induced inflammation in
WAT (Figures S2E and S2F). These results demonstrate that
loss of p75NTR protects against obesity and the metabolic
syndrome.
Loss of p75NTR Increases Energy Expenditure and Fat
Oxidation
Food consumption and energy intake normalized to lean mass
were similar in WT and p75NTR/ mice (Figure 2A), suggesting
that the lean phenotype of p75NTR/ mice might be due to
changes in energy expenditure and not appetite. Indeed, total
oxygen consumption and energy expenditure were dramatically
increased in p75NTR/ compared to WT mice (Figure 2B),Cdespite similar activity levels (Figure S3A). CO2 production was
also greater in p75NTR/ mice (Figure S3B). Increased energy
expenditure was confined to fat oxidation (Figures 2C and S3C).
Given that WAT regulates systemic energy (Rosen and Spie-
gelman, 2014), we analyzed fat oxidation and thermogenesis in
adipocytes. Isolated adipocytes from p75NTR/ mice had 2.4-
fold higher fat oxidation than those from WT mice (Figure 2D),
and 3-fold and 4-fold higher uncoupling protein 1 (Ucp1) and de-
iodonase-2 (Dio2) expression, respectively (Figure 2E). Peroxi-
some proliferator-activated receptors (Ppars) d and g (Ppard
and Pparg, respectively) and Ucp2 were unaffected (data not
shown). Ucp1 protein and RNA, Ppard coactivator-1a (Pgc-1a),
and Ppara gene expression were increased in p75NTR/ WAT
(Figures S3D and S3E). After cold exposure, core body temper-
atures were elevated in p75NTR/mice (Figure S3F). Adiponec-
tin, an adipocyte-derived hormone that increases fat oxidation
(Fruebis et al., 2001) and correlates inversely with insulin resis-
tance (Kadowaki et al., 2006), was higher in serum from
p75NTR/ mice after HFD (Figure 2F). These results are consis-
tent with increased fat oxidation in p75NTR/ adipocytes (Fig-
ure 2C) and insulin sensitivity in p75NTR/ mice (Figures 1E–1I
and S1F–S1H). Adipocyte differentiation markers and lipid accu-
mulation were similar between WT and p75NTR/ adipocytes
(Figures S4A and S4B), suggesting that decreased adipogenesis
was not due to impaired adipocyte differentiation in p75NTR/
mice. Decreased adipogenesis was also not due to alteredell Reports 14, 255–268, January 12, 2016 ª2016 The Authors 257
lipogenesis capacity, as expression of lipogenic genes, including
fatty acid synthase (Fas) and diglyceride acyl-transferase-1
(Dgat1), was not affected (Figure S4C). In brown adipose tissue
(BAT), p75NTR expression did not increasewithHFD (Figure S4D).
Expression of thermogenic genes, fat oxidation, and molecular
markers for brown adipocytes were also not different between
BAT from WT and p75NTR/ mice on a HFD (Figure S4E), sug-
gesting that increased energy expenditure was not due to
p75NTR expression in BAT. These data indicate that loss of
p75NTR promotes fat oxidation and energy expenditure in WAT.
p75NTR Depletion Increases Adipocyte Lipolysis by
Regulating the cAMP/PKA Signaling Pathway
Increased lipolysis in WAT without release of circulating free
fatty acids (FFAs) promotes energy dissipation and fat oxidation
and protects against diet-induced obesity (Ahmadian et al.,
2009). We examined whether lipolysis decreased adiposity in
p75NTR/ mice and increased energy expenditure and fat
oxidation in p75NTR/ adipocytes. While basal rates were un-
changed (Figure S5A), FFA and glycerol release were higher in
WAT explants and MEF-derived adipocytes from p75NTR/
mice after isoproterenol stimulation (Figures 3A, S5B, and
S5C), while circulating FFA levels were unaffected in p75NTR/
mice on aHFD (Figure S5D). Isoproterenol increased FFA release
by 1.6-fold and 2.5-fold in WT and p75NTR/ WAT, respec-
tively (Figure S5B), similar to prior studies (Jaworski et al.,
2009). Neurotrophins did not affect FFA secretion in WT or
p75NTR/WAT (Figure S5E), suggesting that lipolysis is a neuro-
trophin-independent function.
Signaling through the cyclic AMP (cAMP)/protein kinase A
(PKA) pathway primarily regulates lipolysis (Zechner et al.,
2012). We found that lipolysis and cAMP levels were significantly
higher in p75NTR/ compared to WTWAT on a HFD (Figures 3A
and 3B) but not on normal chow (Figures 3B and S5F). Inhibiting
PKA with H-89 decreased FFA release in p75NTR/ WAT (Fig-
ure 3C), indicating that cAMP/PKA signaling is required for
increased lipolysis in p75NTR/WAT. cAMP/PKA signaling pro-
motes lipolysis in WAT via PKA-mediated phosphorylation of
hormone-sensitive lipase (HSL) (Haemmerle et al., 2002; Osuga
et al., 2000). We found that phosphorylated HSL (P-HSL)
was increased in p75NTR/ WAT and MEF-derived adipocytes
(Figures 3D and S5G). Hsl gene expression was increased
by 1.8-fold (Figure S5H), but HSL protein was not significantly
increased in p75NTR/ WAT (Figure 3D) and MEF-derived
adipocytes (Figure S5G). Phosphorylation of other PKA tar-
gets, including perilipin, cAMP response element-binding
protein (CREB) (P-CREB), and p38 (P-p38), were also increased
in p75NTR/ WAT (Figure 3D) and MEF-derived adipocytes
(Figure S5G). These results support that p75NTR regulates lipol-
ysis by modulating cAMP/PKA signaling and catecholamine
sensitivity.
p75NTR Directly Binds the Regulatory and Catalytic PKA
Subunits and Regulates PKA Holoenzyme Dissociation
Dissociation of the PKA subunits is a critical step for PKA activa-
tion (Taylor et al., 2012). To explore how p75NTR regulates cAMP/
PKA signaling, we examined whether p75NTR regulates the tetra-
meric PKA holoenzyme by studying the interaction between the258 Cell Reports 14, 255–268, January 12, 2016 ª2016 The Authorscatalytic (Ca) and regulatory (RIIb) PKA subunits. Intriguingly, the
Ca subunit was dissociated from RIIb in p75NTR/MEF-derived
adipocytes (Figure 3E), despite no differences in protein expres-
sion of PKA subunits (Figure 3F). These results indicate that
p75NTR deletion causes constitutive dissociation and activation
of the PKA catalytic subunit, which agrees with increased
cAMP levels (Figure 3B), lipolysis (Figures 3A and S5B), and
HSL phosphorylation (Figures 3D and S5G) in p75NTR/ adipo-
cytes. p75NTR bound both Ca and RIIb when co-immunoprecip-
itated from overexpression systems (Figure 3G) and endoge-
nously in WAT (Figure 3H). In binding assays, the intracellular
domain of p75NTR (p75ICD) directly interacted with both Ca
and RIIb, but not with the unrelated protein Hsp20 (Figure 3I).
Screening an array library of overlapping p75ICD 25-mer pep-
tides revealed that Ca and RIIb bound within helix 5 (peptides
16–21, amino acids [aa] 348–397) and helix 6 (peptides 23–25,
aa 383–417) of the death domain (DD) of p75ICD, respectively
(Figure 4A). An alanine scanning substitution array of p75ICD
identified key residues that enable its interaction with Ca (residue
C379) and RIIb (residues P380, R382, L385, R404, R405, and
R408) (Figures 4B and 4C). Thus, we performed site-specific
mutagenesis of p75NTR (Figure 4D) and found that the C379A
mutation abolished its interaction with Ca, while mutations of
the other residues for RIIb abolished its interaction with RIIb (Fig-
ures 4E and 4F). These results support the finding that p75NTR
directly interacts with PKA subunits through motifs within its DD.
Next, we tested in adipocytes the interaction of p75NTR with
cAMP-degrading phosphodiesterases (PDEs) and the functional
consequences of p75NTR mutants that disrupt the interaction
of p75NTR with PKA subunits. Consistent with our prior study
(Sachs et al., 2007), p75NTR co-immunoprecipitated with
cAMP-hydrolyzing enzyme phosphodiesterase 4A5 (PDE4A5) in
WAT and adipocytes (Figure S6A). Lentiviral expression of WT
p75NTR or p75NTRC379A reduced P-HSL levels in p75NTR/
MEF-derived adipocytes by 2-fold and 1.5-fold, respectively
(Figure 4G). Expression of the p75NTR2M mutant, which reduces
binding of p75NTR to PKA-RIIb, did not alter P-HSL (Figure 4G).
We performed these analyses with isoproterenol (Figure 4G),
because at baseline, control lentivirus increased basal levels of
P-HSL (Figure S6B). Lentiviral expression of both WT p75NTR
and p75NTRC379A reduced cAMP levels (Figure S6C), suggest-
ing that p75NTR regulates cAMP/PKA signaling through multiple
pathways.
Adipocyte-Specific p75NTR Knockout Protects from
HFD-Induced Obesity and Insulin Resistance
To investigate how adipose tissue contributes to the lean pheno-
type and insulin sensitivity of p75NTR/ mice on a HFD, we
depleted p75NTR specifically in adipocytes (p75AKO) by crossing
conditional p75NTR knockout (p75F/F) (Bogenmann et al., 2011)
with aP2-cre (Adipocyte-cre) mice, which show gene recombi-
nation specifically in adipocytes without gene recombination in
brain, muscle, liver, stromal vascular cells, and macrophages
(Ahmadian et al., 2011; Barak et al., 2002; He et al., 2003; Lee
et al., 2014; Li et al., 2011; Paschos et al., 2012; Qi et al.,
2009). In p75AKO mice, p75NTR was specifically deleted in adi-
pose tissue and not the brain and muscle (Figures 5A and 5B).
Strikingly, p75AKO mice weighed significantly less (Figure 5C)
Figure 3. p75NTR Regulates Lipolysis via cAMP/PKA Signaling
(A) Isoproterenol-stimulated FFA and glycerol levels in WAT from WT and p75NTR/ mice on a HFD. **p < 0.01; ***p < 0.001, two-way ANOVA. n = 8 mice per
group.
(B) cAMP accumulation in WAT from WT and p75NTR/mice on normal chow (ND) or 10 weeks (w) on a HFD. *p < 0.05, ns, not significant, unpaired Student’s
t test. n = 4 mice per group.
(C) FFA levels in WAT treated with the PKA inhibitor, H-89 from WT, and p75NTR/ mice on a HFD (WT or p75NTR/ versus p75NTR/ treated with H-89.
***p < 0.001, two-way ANOVA. n = 5 mice per group.
(D) P-HSL, HSL, P-p38, p38, P-CREB, CREB, and p75NTR protein expression (left) and immunoprecipitation (IP) of lysates with anti-perilipin followed by western
blottingwith anti-phospho-PKA (p-PKA) to detect all PKA-phosphorylation sites on perilipin and total perilipin expression (n = 2mice per group) (right) inWAT from
WT and p75NTR/ mice on HFD. Phospho-perilipin levels normalized to GAPDH were quantified by densitometry (D represents fold changes). Representative
immunoblots are shown from n = 12 mice per group.
(E) Immunoprecipitation of PKA-Ca protein followed by western blotting to detect PKA RIIb and RIIa fromWT and p75NTR/MEF-derived adipocytes treated or
not with isoproterenol (ISO). Representative immunoblot from three independent experiments.
(F) PKA-Ca, PKA-RIIb, and PKA-RIIa protein expression in WT and p75NTR/ MEF-derived adipocytes. Representative immunoblots from three independent
experiments.
(G) Immunoprecipitation of HA-PKA-Ca protein (top) andmyc-PKA-RIIb (bottom) followed bywestern blotting to detect GFP-p75NTR in 293T cells overexpressing
indicated constructs. Representative immunoblots from three independent experiments.
(H) Immunoprecipitation of PKA-RIIb (top) and PKA-Ca (bottom) protein followed by western blotting to detect p75NTR in WAT from WT mice. Representative
immunoblots from three independent experiments.
(I) ELISA binding assays between recombinant His-p75ICD and increasing concentrations of His-PKA-Ca (left) and PKA-RIIb (right). His-Hsp20 was used as a
control. Results are from three independent experiments performed with duplicates. Kd values were estimated using a one-site binding model.
Data are shown as means ± SEM.
See also Figure S5.and showed improved glucose and insulin tolerance (Figure 5D),
suggesting that specifically deleting p75NTR from adipose tissue
protects against diet-induced obesity and type 2 diabetes. In
addition, livers from p75AKO mice on a HFD showed reduced
SREBP-1 and hepatic lipid accumulation compared to WT
mice (Figures S7A and S7B). In contrast, muscle-specific
knockout mice (p75SKMKO) had weight gain similar to that ofCp75F/F and muscle creatine kinase (MCK)-cre (SKM-cre) control
mice (Figures 5E and 5F). These results support the reduced
body weight gain and increased insulin sensitivity in p75NTR/
mice on a HFD, demonstrating that deleting p75NTR from adipo-
cytes protects against HFD-induced obesity and insulin resis-
tance. p75AKO mice showed increased energy expenditure and
fat oxidation, despite similar activity and no changes in foodell Reports 14, 255–268, January 12, 2016 ª2016 The Authors 259
Figure 4. p75NTR Interacts with the PKA Ca Subunit to Regulate Lipolysis
(A) Peptide array mapping of the p75ICD sites required for the interaction with PKA-Ca and PKA-RIIb. Schematic diagram of p75ICD shows the domain or-
ganization and peptide location, length, and sequences. TM, transmembrane domain; JX, juxtamembrane domain.
(B) Alanine scanning substitution arrays of the identified interacting p75NTR peptides 360–384 and 375–399 probed with PKA-Ca. Red amino acids indicate
substitutions that block the interaction.
(C) Alanine scanning substitution arrays of interacting p75NTR peptides 368–392, 383–407, and 388–412 probed with PKA-RIIb. Highlighted in red are the aa
whose substitution blocks the interaction.
(D) p75NTR mutant constructs generated.
(E) Immunoprecipitation of myc-PKA-Ca protein followed by western blotting to detect HA-p75NTR WT and HA-p75NTRC379A or HA-p75NTR 3M in 293T cells
overexpressing indicated constructs. Representative immunoblots are shown from three independent experiments.
(F) Immunoprecipitation of myc-PKA-RIIb protein followed by western blotting to detect HA-p75NTR WT and HA-p75NTR P380A, HA-p75NTR R404A, HA-p75NTR
2M, or HA-p75NTR 3M in 293T cells overexpressing indicated constructs. Representative immunoblots from three independent experiments.
(G) P-HSL, HSL, and p75NTR protein expression in WT and p75NTR/ MEF-derived adipocytes infected with lentiviral vectors overexpressing the indicated
constructs and treated or not with isoproterenol (ISO). Representative immunoblots from three independent experiments.
See also Figure S6.consumption and energy intake (Figures 6A–6C and S7C–S7E),
similar to p75NTR/ mice on a HFD (Figures 2 and S3A–S3C).
WAT isolated from p75AKO mice showed increased metabolic
rates via increased expression of thermogenic, brown adipose
identity, and lipolytic genes such asDio2,Ucp-1, Pgc-1a, Ppara,
and Hsl (Figure 6D). HSL phosphorylation was also increased in
WAT of p75AKO compared to control mice (Figure 6E). These re-
sults indicate that adipose-specific expression of p75NTR is a
major contributor to obesity, energy expenditure, and lipolysis.
To further analyze the adipose-specific role of p75NTR in vivo,
we transplanted epididymal fat pads from p75NTR/ mice
into the visceral area of WT (p75NTR//WT) mice (Figure 7A).
After 6 weeks on a HFD, the increase in body weight was signif-
icantly lower in p75NTR//WT compared to WT/ WT WAT260 Cell Reports 14, 255–268, January 12, 2016 ª2016 The Authorsor sham-operated controls (Figure 7B). p75NTR// WT mice
also showed improved glucose and insulin tolerance 10 weeks
after a HFD (Figure 7C). Insulin sensitivity was unaffected in
WT / WT or sham-operated mice (Figure 7C), as expected
(Tran et al., 2008). The effect of p75NTR/ WAT transplantation
on body weight and insulin sensitivity on WT mice is significant,
and the values obtained are at a range similar to that observed in
other transplant studies (Chen et al., 2003; Minamino et al.,
2009).WT/p75NTR/mice remained lean and insulin sensitive
upon a HFD (Figures 7D–7F), likely because they retained a sub-
stantial amount of p75NTR/ fat. These results indicate that
p75NTR expression in WAT regulates fat oxidation, thermogene-
sis, lipolysis, and HFD-induced weight gain and insulin resis-
tance in mice.
Figure 5. p75NTR Deficiency in WAT Protects Mice from HFD-Induced Obesity and Insulin Resistance
(A) p75NTR protein expression in WAT and the CNS from p75F/F, Adipocyte-cre, and p75AKO mice (n = 5 mice per group). Representative blot is shown.
(B) p75NTR expression in brain, WAT (epididymal fat), SUBC (subcutaneous inguinal fat), BAT, Soleus (skeletal muscle), kidney, and heart from Adipocyte-cre and
p75AKO mice (n = 5 mice per group).
(C) Body weight of p75F/F (n = 18), Adipocyte-cre (n = 7), and p75AKO (n = 10) mice on a HFD. **p < 0.01; ***p < 0.001, two-way ANOVA.
(D) Glucose (left) and insulin tolerance (right) tests inAdipocyte-cre (n = 7) and p75AKO (n = 10) mice after 8 weeks on a HFD. *p < 0.05; **p < 0.01; ***p < 0.001, two-
way ANOVA.
(E) p75NTR protein expression in skeletal muscle from p75F/F (n = 3), SKM-cre (n = 2), and p75SKMKO mice (left) (n = 3). Quantifications of western blot analysis
for p75NTR in skeletal muscle from p75F/F, SKM-cre, and p75SKMKO mice (right). **p < 0.01, Tukey’s multiple comparisons test and one-way ANOVA; ns, not
significant.
(F) Body weight of p75F/F (n = 18), SKM-cre (n = 10), and p75SKMKO (n = 15) mice on a HFD (ns, not significant, two-way ANOVA).
Data are shown as means ± SEM.
See also Figure S7.DISCUSSION
Many studies have addressed the key mechanisms in adipo-
cytes that regulate energy balance, but the molecular links be-
tween diet, energy storage and mobilization, and signaling
remain unclear. While studies have shown that neurotrophins
and their receptors regulate appetite (Lyons et al., 1999; Xu
et al., 2003b), we report a surprising role for the neurotrophin re-
ceptor p75NTR in adipose tissue. We found that p75NTR is
upregulated in adipocytes after a HFD, where it directly sup-
presses PKA activity to attenuate lipolysis, fat oxidation,
and thermogenesis and renders adipose tissue resistant to cate-
cholamine stimulation. Although p75NTR/ mice did not showCdifferences in appetite or physical activity, they were protected
against diet-induced weight gain, type 2 diabetes, atheroscle-
rosis, inflammation, and hepatic steatosis, suggesting that
p75NTR regulates obesity and its comorbidities. In cell-autono-
mous systems, p75NTR did not affect fat cell differentiation,
which further supports its specificity in regulating cAMP/PKA
signaling and thermogenesis. Additionally, specifically depleting
p75NTR in adipocytes protected mice from HFD-induced obesity
and insulin resistance. In contrast, loss of BDNF and TrkB regu-
late body weight by increasing appetite on normal chow (Lyons
et al., 1999; Xu et al., 2003b). Therefore, the metabolic outcome
of neurotrophin receptor signaling in vivo may depend on the
balance between neurotrophin-dependent central regulation ofell Reports 14, 255–268, January 12, 2016 ª2016 The Authors 261
Figure 6. p75NTR Deficiency in WAT Increases Thermogenesis and Lipolysis
(A) Oxygen consumption normalized to lean body mass in Adipocyte-cre and p75AKO mice on a HFD (n = 6 mice per group).
(B) Food consumption (left) and energy intake (right) of Adipocyte-cre (n = 10) and p75AKO (n = 12) mice over 4 days after 10 weeks of a HFD. ns, not significant,
unpaired Student’s t test.
(C) Fat oxidation normalized to lean body mass in Adipocyte-cre and p75AKO mice on HFD (***p < 0.001, unpaired Student’s t test; n = 6 mice per group).
(D) Ucp1, Hsl, Pgc-1a, Ppara, and Dio2 RNA expression in WAT from p75F/F, Adipocyte-cre, and p75AKO mice on a HFD. *p < 0.05; **p < 0.01, Tukey’s multiple
comparisons test and one-way ANOVA; ns, not significant. n = 4 mice per group.
(E) P-HSL and HSL protein expression in WAT from p75F/F (n = 2), Adipocyte-cre (n = 3), and p75AKO (n = 2) mice on a HFD.
Data are shown as means ± SEM.
See also Figure S7.food intake by BDNF/TrkB signaling and neurotrophin-indepen-
dent peripheral regulation of energy expenditure in fat by p75NTR.
Thus, developing agents that target p75NTR in the periphery may
provide an attractive therapeutic intervention for preventing
obesity, liver steatosis, and diabetes.
Loss of p75NTR dramatically increased cAMP levels and PKA
activity in adipocytes. Because anchoring proteins regulate
spatiotemporal control of cAMP/PKA signaling (McConnachie
et al., 2006), p75NTR may maintain the PKA holoenzyme in
an inactive state and might also be part of a multienzyme
anchor complex that coordinates PKA to specific subcellular
locations. We show that p75NTR directly interacts with the regu-
latory (RIIb) and catalytic (Ca) subunits of PKA. Interestingly, ge-
netic deletion of RIIb remarkably resembles the phenotype of
p75NTR/ mice, since RIIb/ mice are also resistant to HFD-
induced obesity and type 2 diabetes (Cummings et al., 1996;
Schreyer et al., 2001). In mice, it induces a compensatory in-
crease in the RIa subunit, generating a tetrameric holoenzyme
that binds more avidly to cAMP (Cummings et al., 1996). In
contrast, we showed that deleting p75NTR causes dissociation
of the PKA subunits without affecting the levels of RIa. These re-
sults suggest that changes in both the levels of the PKA subunits
and modifications of the conformation of the PKA holoenzyme
might control the lipolytic pathway in adipocytes. Triggering
b-adrenergic receptors in adipocytes stimulates energy expen-
diture by cAMP-dependent increases in lipolysis and fatty-acid
oxidation (Song et al., 2010). Our study shows similar effects be-262 Cell Reports 14, 255–268, January 12, 2016 ª2016 The Authorstween isoproterenol-stimulated and p75NTR/ adipocytes, sug-
gesting that loss of p75NTR increases cAMP and lipolysis. Thus,
the interaction between p75NTR and PKA regulates the formation
of the PKA holoenzyme, and p75NTR deletion increases cAMP
levels, constitutive PKA dissociation, lipolysis, and energy
expenditure. Interestingly, feedback mechanisms reciprocally
link cAMP levels and PKA activity—PKA phosphorylation can
inhibit adenylyl cyclases and increase PDE4 activity (Iwami
et al., 1995; MacKenzie et al., 2002)—which could be affected
in p75NTR/ adipocytes. Future studies that knock out PDE4A,
PKA-Ca, and PKA-RIIb subunits from mice may reveal how the
p75NTR-controlled PKA dissociation contributes to cAMP/PKA
signaling in adipocytes. Also, generating novel knockin mouse
models with point mutation(s) that selectively inhibit the interac-
tion between p75NTR and PKA in vivo may reveal the relative
contribution of p75NTR signal transduction pathways in meta-
bolic diseases and other biological functions within and outside
of the nervous system.
p75NTR interacts with both PKA and PDEs, and PKA works
with PDEs to create a signaling complex, or ‘‘signalosome’’ (Tay-
lor et al., 2012). Similar to p75NTR, A-kinase anchoring proteins
(AKAPs) directly bind PKA and PDEs to compartmentalize
cAMP/PKA signaling by associating with target effectors, sub-
strates, and signal termination (Baillie et al., 2005; Carr et al.,
1991; Dodge-Kafka et al., 2005). Canonical AKAPs are charac-
terized by the specific amphipathic helix of 14–18 aa that bind
PKA subunits (McConnachie et al., 2006). Although p75NTR
Figure 7. p75NTR-Deficient WAT Transplantation Reduces Body Weight and Insulin Resistance
(A) Schematic of fat transplantation for WT mice. Epididymal fat from p75NTR/, WT, and no fat (sham) was transplanted in WT mice. All animals after surgery
were fed a HFD.
(B) Body weight of WTmice transplanted with p75NTR/ fat (n = 9), WT fat (n = 9), and sham (n = 5) (WT/WT versus p75NTR//WT). *p < 0.05; **p < 0.01, by
two-way ANOVA.
(C) Glucose (left) and insulin tolerance (right) tests in WT-transplanted mice after 8 weeks on a HFD (p75NTR//WT versusWT/WT). **p < 0.01; ***p < 0.001,
by two-way ANOVA (n = 4).
(D) Schematic of fat transplantation. Epididymal fat from p75NTR/, WT, and no fat (sham) was transplanted in p75NTR/mice. All animals after surgery were fed
a HFD.
(E) Body weight of WT and p75NTR/mice transplanted with p75NTR/ (n = 9) or WT fat (n = 9) and sham-operated (n = 4) (WT sham versus WT/ p75NTR/).
**p < 0.01; ***p < 0.001, two-way ANOVA.
(F) Glucose (left) and insulin tolerance (right) tests in recipient mice after 10 weeks of a HFD (WT sham versusWT/ p75NTR/). *p < 0.05; **p < 0.01; ***p < 0.001,
two-way ANOVA. n = 4 mice per group.
Data are shown as means ± SEM.does not contain the AKAP amphipathic helix, p75NTR might
function as a non-conventional AKAP-regulating PKA signal by
directly binding both PKA subunits and PDEs. Moreover, given
that regulation of PKA is critical in metabolism and neuronal
functions, p75NTR might regulate cAMP/PKA signaling in neu-
ronal cells (Zhong et al., 2009). Structural biology studies are
needed to understand the PKA holoenzymes and macromolec-
ular assemblies that regulate cAMP/PKA signaling (Kim et al.,
2007; Zhang et al., 2012). These studieswill determine the contri-
bution of a potential PDE4A-p75NTR-PKA macromolecular com-
plex in cAMP regulation and will characterize the properties of
p75NTR as a ‘‘non-conventional’’ AKAP in peripheral tissues
and the brain.
p75NTR/ mice were protected against HFD-induced insulin
resistance through significantly enhanced insulin sensitivity in
skeletal muscle, hepatic, and adipose tissue. Since p75NTR/
mice remain lean on HFD, their resistance to type 2 diabetes
could be a secondary effect to reduced body weight. Increased
insulin sensitivity in p75NTR/mice on normal chow (Baeza-Raja
et al., 2012) might also contribute to reduced insulin resistance
upon HFD. p75AKO mice and p75NTR/ / WT mice showed
increased systemic insulin sensitivity after HFD, emphasizingCthe primacy of WAT in systemic insulin regulation and its
communication with other key metabolic organs to enhance
insulin sensitivity. In this regard, p75NTR/ mice showed sub-
stantial increases in circulating levels of adiponectin, an adipo-
cyte-derived hormone that reduces insulin resistance and liver
steatosis by increasing fat oxidation via the AMP-activated pro-
tein kinase pathway (Fruebis et al., 2001; Xu et al., 2003a).
Increased lipolysis induces fatty acid oxidation. Thus, potential
increases in oxidation could also be interpreted as conse-
quences of increased lipolysis. For example, reciprocal regula-
tion of lipolysis and fat oxidation associated with crosstalk
between the cAMP/PKA pathway and Sirt-1 regulates fatty
acid oxidation (Gerhart-Hines et al., 2011). Our study shows
that p75NTR does not regulate adipocyte differentiation, which
supports prior studies showing that defects in lipolysis do
not affect adipocyte differentiation. For example, similar to
p75NTR/ mice, adipose-specific phospholipase A2 (AdPLA)
knockout adipocytes showed normal intracellular lipid accumu-
lation and significantly increased lipolysis (Jaworski et al., 2009).
Regulation of lipolysis without effects in adipocyte differentiation
suggests that lipolysis is a primary effect of p75NTR. p75NTR/
mice show increased lipolytic rates without increasing serumell Reports 14, 255–268, January 12, 2016 ª2016 The Authors 263
fatty acids, suggesting that increased fatty acid oxidation
protects p75NTR/ mice from increased lipolysis. Indeed,
adipocytes can increase FFA use and energy expenditure
without increasing serum fatty acid levels (Ahmadian et al.,
2009). Thus, weight reduction and increased lipid oxidation
might be due, in part, to increased synthesis of adiponectin or
other adipokines or metabolites derived from WAT. While
glucose tolerance significantly improved in p75AKO and
p75NTR/ / WT mice 8 weeks after HFD, it was reduced
compared to p75NTR/mice tested 20 weeks after HFD. These
differencesmay be due to effects of p75NTR expression in tissues
other than adipose tissue or to different time points used to mea-
sure glucose tolerance.
Our study shows increased P-HSL in WAT isolated from
p75NTR/ (Figure 3D) and p75AKO mice (Figure 6E), and in
p75NTR/ MEF-derived adipocytes cultured in vitro (Fig-
ure S5G), indicating that p75NTR loss similarly increases P-HSL
in WAT and MEF-derived adipocytes. As expected, the relative
fold changes are different between tissue isolated from mice
(Figure 3D) and cultured cells (Figure S5G). The 1.8-fold and
2.3-fold increases in Hsl RNA in p75NTR/ WAT (Figure S5H)
and p75AKO mice (Figure 6D), respectively, did not change total
HSL protein. These results further suggest that p75NTR contrib-
utes to PKA-mediated phosphorylation of HSL (Figures 3D
and 6E) and are consistent with prior studies showing that HSL
is primarily regulated post-translationally (Kraemer and Shen,
2002). We also found7-fold and 2.5-fold increases in P-HSL
in WAT isolated from p75AKO and control Adipocyte-Cre mice,
respectively. Since phosphorylation of HSL in vivo depends
on fasting conditions (Kraemer and Shen, 2002), variability in
P-HSL within animals may be due to their responses to fasting.
Regardless of the expected variability of signal transduction
in vivo, the increase in P-HSL in p75AKO mice supports the
data obtained in vivo in p75NTR/ mice and in vitro in
p75NTR/MEF-derived adipocytes showing that p75NTR deple-
tion in fat increases HSL phosphorylation. We also evaluated
PKA-mediated phosphorylation of perilipin by pulling down peril-
ipin and blotting with P-PKA (Choi et al., 2010; Marcinkiewicz
et al., 2006). Our study tested phosphorylation of all six potential
PKA phosphorylation sites on perilipin (Greenberg et al., 1993;
Zhang et al., 2003). Future studies will map the potential specific
phosphorylation sites of perilipin that are regulated by p75NTR.
While p75NTR is expressed in all tissues involved in metabolic
regulation, our genetic and transplantation studies support that
WAT is the primary site of action for p75NTR. Similar to
p75NTR/ mice, specifically deleting p75NTR from adipocytes
also protected against HFD-induced obesity, while specifically
deleting it from muscle did not. Furthermore, primary cultures
of p75NTR/ adipocytes had dramatically increased lipolysis,
fat oxidation, and thermogenesis. Moreover, p75NTR// WT
mice were protected from increased body weight after a HFD.
Although these studies cannot exclude the potential effect of
secreted factors by WAT, they strongly support the finding that
deleting p75NTR from adipocytes has beneficial metabolic ef-
fects. p75NTR was upregulated in WAT after exposure to a
HFD. Although transcription factors, such as CLOCK/BMAL,
regulate p75NTR expression (Baeza-Raja et al., 2013), the tran-
scriptional mechanisms that control its upregulation after injury264 Cell Reports 14, 255–268, January 12, 2016 ª2016 The Authorsor disease remain unknown. Thus, proinflammatory signals
might increase p75NTR levels in WAT upon HFD. These results
suggest that adipose tissue is a primary site for p75NTR to func-
tionally regulate body weight, insulin resistance, lipolysis, and
energy expenditure. Future studies will explore the potential
contribution of p75NTR expression in other tissues, such as the
nervous system, liver, skeletal muscle, macrophages, and BAT
to its metabolic functions.
Our data show that HFD increases p75NTR expression. In
accordance with our prior work (Sachs et al., 2007), cAMP/
PKA signaling is inhibited in p75NTR-expressing cells. Several
signaling pathways are activated after ligands bind to p75NTR;
however, p75NTR also contributes to many signaling pathways
and biological functions independent of ligands (Barker, 2004;
Teng and Hempstead, 2004; Zampieri and Chao, 2006). For
example, p75NTR can serve as a co-receptor for receptors other
than neurotrophins, such as the Nogo receptor and ephrin-As
(Domeniconi et al., 2005; Lim et al., 2008; Wong et al., 2002).
p75NTR can also induce signaling independent of neurotrophins
and/or function as a co-receptor. Prior studies suggested that
p75NTR may signal in a neurotrophin-independent manner in
neuronal cells to induce apoptosis (Majdan et al., 1997; Rabiza-
deh et al., 1993) and activate PI3 kinase (Roux et al., 2001), RhoA
(Yamashita et al., 1999), PDE4A (Sachs et al., 2007), hypoxia
inducible factor (HIF)-1a (Le Moan et al., 2011), and transforming
growth factor (TGF)-b (Schachtrup et al., 2015). In these studies,
expressing p75ICD alone could exert a signaling event and
biological effect without a neurotrophin ligand. Moreover, cross-
linking of p75NTR dimers constitutively activates several path-
ways independent of ligands (Vilar et al., 2009). Since p75NTR
is not constitutively expressed but is upregulated upon a HFD,
its expression could trigger activation of a signaling pathway.
Since tumor necrosis factor (TNF)-a and interleukin (IL)-1b
induce p75NTR expression, increased pro-inflammatory activity
upon HFD might augment p75NTR levels (Choi and Friedman,
2009). There are several examples of well-established ligand-in-
dependent signaling pathways in other receptor systems. For
example, steroid hormone receptors (Power et al., 1991), scav-
enger receptors (Li et al., 2005), viral G-protein-coupled recep-
tors (Vischer et al., 2006), androgen receptors (Culig, 2004),
and B cell receptors (Monroe, 2004) all signal in a ligand-inde-
pendent manner. Future studies will address the potential
endogenous mechanisms that increase expression of p75NTR
upon HFD.
In prior studies, p75NTR/mice have shown many physiolog-
ical phenotypes, including deficits in sensory nerve development
(Lee et al., 1994), neurogenesis (Young et al., 2007; Zuccaro
et al., 2014), and insulin resistance (Baeza-Raja et al., 2012). In
animal models of disease, p75NTR/ mice have also shown
many pathological phenotypes, such as deficits in oligodendro-
cyte apoptosis (Beattie et al., 2002), liver regeneration (Passino
et al., 2007), retinal hypoxia (Le Moan et al., 2011), and astrocyte
functions (Schachtrup et al., 2015). Our study identified a funda-
mental role for p75NTR in metabolism, given the dramatic resis-
tance of p75NTR/ mice to diet-induced obesity. Proteins such
as p75NTR, which are expressed in several tissues and control
multiple signaling pathways, commonly have pleiotropic biolog-
ical functions in vivo. For example, many phenotypes have been
seen in the brain and peripheral tissues of mice depleted of tran-
scription factors such as nuclear factor kB (NF-kB) and Sirt-1, or
scaffold proteins such as b-arrestin. We have shown that
p75NTR/mice have reducedHIF-1a and are resistant to hypox-
ia (Le Moan et al., 2011). Indeed, fat-specific depletion of HIF-1a
improves insulin sensitivity and decreases adiposity in HFD-fed
mice (Jiang et al., 2011). Since p75NTR/ mice have reduced
HIF-1a only after exposure to hypoxic conditions, local tissue
hypoxia in fat might decrease HIF-1a in p75NTR/ fat after
HFD. This mechanism would support our model, since depletion
of either HIF-1a or p75NTR shows similar phenotypes upon diet-
induced obesity. We have also shown that p75NTR/ mice had
no significant differences in circadian rhythms in vivo (Baeza-
Raja et al., 2013), suggesting that circadian regulation is unlikely
to affect the metabolic phenotype of the p75NTR/ mice. The
dramatic biological effect of p75NTR in obesity suggests that
metabolic regulation could be one of the most critical in vivo
functions for p75NTR. Further, p75NTR/ mice on an HFD could
be an experimental model for studying mechanisms of obesity
and energy balance.
In summary, this study demonstrates that the obesity-depen-
dent induction of p75NTR in WAT represses lipolysis and energy
expenditure by directly binding and regulating the PKA holoen-
zyme dissociation, thus majorly contributing to the generation
of obesity. By developing agents that target the p75NTR ICD in
the periphery, we may discover attractive therapeutic strategies
to increase energy expenditure and prevent obesity, liver steato-
sis, and diabetes.
EXPERIMENTAL PROCEDURES
Animals
WT, p75NTR/ (Lee et al., 1992), adipocyte-cre (aP2-cre) (He et al., 2003),
and MCK-cre (Br€uning et al., 1998) mice were in a C57BL/6J background (The
Jackson Laboratory). Heterozygous p75NTR+/ mice were crossed to obtain
p75NTR/, p75NTR+/, and p75NTR+/+ littermates. p75NTRflox/flox (p75F/F) (Bogen-
mann et al., 2011) mice in the C57BL/6J backgroundwere also used. Crossings
between p75F/F and Adipocyte-cre or MCK-cre were performed to generate
p75AKO (AP2-cre::p75NTRflox/flox) or p75SKMKO (MCK-cre::p75NTRflox/flox) mice.
Male mice 9–25 weeks old were used. Mice were housed under a 12 hr:12 hr
light:dark cycle, fed a standard chow or a HFD (60% calories from fat,
D12492,ResearchDiets), andhadaccess to foodandwater ad libitum.All animal
experiments were performed under the guidelines set by the Institutional Animal
Care andUseCommittee of the University of California, San Francisco, and Uni-
versity of California, San Diego, and are in accordance with the NIH.
Metabolic Cages
The Comprehensive Lab Animal Monitoring Systems (Columbus Instruments)
was used to measure food intake, movement, volume of carbon dioxide
produced (VCO2), volume of oxygen consumed (VO2), respiration rate
(RER = VCO2/VO2), and caloric output [(3.815 + 1.232 3 RER) 3 VO2] over
5 consecutive days. Mice were housed in individual cages for 5 days and al-
lowed to acclimate in the recording metabolic chambers for 24 hr before the
start of measurements to minimize stress. Mouse weights and body composi-
tion were determined before the monitoring period. Body composition was
determined by quantitative magnetic resonance on the EchoMRI 3-in-1
body composition analyzer (EchoMRI). Fat and lean mass were determined
by the system software. Data were normalized to body weights, except VO2
and VCO2, which were normalized to lean mass. Fat oxidation was calculated
using the formula [(1.695 3 VO2)  (1.701 3 VCO2)] 3 9. Values were normal-
ized by lean mass. Measurements of energy intake and energy expenditure
were averaged over four light and dark periods.CCo-immunoprecipitation
Co-immunoprecipitation was performed as described previously (Le Moan
et al., 2011). Cell lysates were prepared in 1% NP-40, 200 mM NaCl, 1 mM
EDTA, and 20 mM Tris-HCl (pH 8.0). Rabbit anti-p75NTR antibody 9992 (a
kind gift from Moses Chao), rabbit anti-PKACa (Cell Signaling), and rabbit
anti-perilipin (Cell Signaling) were used for IP, and immunoblots were per-
formed with anti-PKACa, anti-PKARIIa, anti-PKARIIb, anti-PDE4A, anti-phos-
pho PKA substrate, and anti-p75NTR. Additionally, rabbit anti-HA (hemaggluti-
nin) and mouse anti-Myc were used for IP, and immunoblots were performed
with anti-GFP, anti-HA, and anti-Myc.
cAMP, Active PKA, Adiponectin, Triglycerides, and Cholesterol
cAMP (Assay Designs) and active PKA (Enzo Life Sciences) were measured
following manufacturer’s instructions. Forskolin (10 mM; Sigma) was added
for 1 hr. Adiponectin in serumwasmeasured by ELISA (B-Bridge International),
according to manufacturer’s instructions. Liver triglycerides (Abcam) were
measured following manufacturer’s instructions. Total blood cholesterol was
measured using PTS Panels test strips (Polymer Technology Systems) on
blood samples collected from animals after fasting.
Statistical Analysis
Statistical significance was calculated with GraphPad Prism (GraphPad Prism
Software) by an unpaired two-sided Student’s t test to analyze significance be-
tween two experimental groups or by non-parametric two-sided Mann-Whit-
ney test, Tukey’s multiple-comparisons test, one-way ANOVA, or two-way
ANOVA for multiple comparisons followed by a Bonferroni’s post-test. Data
are shown as means ± SEM.
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